ABG Sundal Collier acted as Joint Global Coordinator and Bookrunner in the rights issue of SEK 263 million in Q-linea AB

Q-linea AB (“Q-linea” or the “Company”), the innovative infection diagnostics company, has successfully raised SEK 263 million in a rights issue. The proceeds will primarily be used to finance Q-linea’s updated market strategy, where the focus is on building its own sales force in key geographies and at the same time enter into agreements with distributors to increase the reach of the marketing of ASTar as well as to finance regulatory studies for ASTar.
Q-linea develops medical instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s first product, ASTar, was launched on the European market in the fall of 2021 and the Company submitted the application for market approval for the US market in June 2022. In the coming years, Q-linea plans to expand the product offering for ASTar with expanded panels. The plan is to initially expand the panel for Gram positive bacteria for patients with blood infections, and in the long term broaden the geographical availability. The Company’s shares are listed in Sweden on Nasdaq Stockholm.